[바이오 유망기업]⑨ Utrex reserves the "world leading company" for the next generation of immunocarcinogens



[ad_1]

[이데일리 이미나 기자]

[이데일리 김지섭 기자] "Innovative drug-based immunotherapeutic technologies will develop cellular therapeutic and antibody antibodies, and through rapid commercialization, they will become a leading role in immunosuppressive drugs."

Kwon Byung-se, a representative of the gadget, met with reporters at the Plaza Hotel in Jung-gu in Seoul on 16 September.

Utrex is a biotechnology company that develops medicines for unacceptable diseases, such as cancer, with immunotherapy using an "immune system" that protects viruses and toxins in the human body. The statement on the mission "Utrex" also showed the intention to develop new immunotherapeutic drugs, such as "EU" (new), "TI" (immune therapy) and "LEX" (method).

The immunotoxicant treats cancer cells with a normal immune system or strengthens the attenuated immune system in various ways to remove cancer cells. Compared to conventional medicines used to treat cancer or target cancers that attack specific cancer cells, they are less resistant to drugs and are safe from adverse effects such as leukopenia and hair loss. According to GBI Research, the market for immunotherapy drugs is expected to grow at an average annual rate of 23.9% from $ 18 billion in 2015 to 86 trillion gains in 2022.

◇ Immunological research "Hanwoo" … The original technology for immunotherapy has been obtained

Kwon Byung-seh, who founded Utilities in February 2015, is an authority in the field of immunology, which deals with the sale of kangwoo products. He was a professor of chemistry and biology at Ulsan University and Head of the Department of Immunocytochemistry at the National Center for Cancer at Yale University. Kwon said: "The study of immunology for the last 40 years has led to the development of differentiated immunotherapy."

In particular, it was first observed in 1989 when it detected the "4-1BB" receptor that promotes "T cells" associated with the immune modulating antibody. T cells, immune cells, attack and destroy cancer cells. 4-1BB can selectively activate or reduce immune cell activation function. T. Utrex uses it to separate and cultivate T cells from the blood of cancer patients and then injects it into the body of the patient.

(Celica EBViNT), which treats lymphoma, laryngeal cancer, gastric cancer, etc., is a single-phase glioblastoma / malignant tumor that treats ½ phase, non-small cell lung cancer and breast cancer. The cell of WTiNT, which treats the glioma, etc., is in the first stage. "Aptity Cell will finish its second phase of clinical trials by 2020," he said. "The purpose is to grant the US Food and Drug Administration (FDA) a license in 2022 by designating innovative medicines."

In addition, treating a third cell (CAR-T) that expresses a chimeric antigen antigen receptor that improves anti-cancer effect by introducing a gene that successfully detects and destroys cancer cells in T cells (CAR). The existing CAR-T therapeutic agent has caused unwanted effects such as cytokine syndrome that attack normal cells indiscriminately and cause hypotension and acute renal damage. However, the CAR-T device therapy reduced the adverse effects by attacking only malignant cells that directed the "HDL-DR" antigen that was expressed when normal cells turned into malignant cells. By standardizing the production process and standardizing the product, the cost of the drug, which reached several hundred million victories, significantly decreased. Other drugs, such as EU101 and EU102, are active in the treatment of cancer cells by activating the immune response of T cells.

These new developmental drugs are actively seeking technological exports. Kwon said: "Now we have a lot of technologies, but it's impossible to develop." He said: "We will increase clinical costs through technology exports and cooperate with global pharmaceutical companies to create success stories."

◇ New drug development in the US, like the bridge … "Aspiration Global Pharma"

Kwon's main priority is to establish a bridge in the US and Europe for the development of new drugs. In September, we signed a Memorandum of Understanding with the US JGBLI (JG Business Link International) and ABB Anti-Cell for successful entry into the US. JGBLI will support R & D centers in the United States and consult the Maryland Pharmaceuticals Department for approval of anti-cancer medicines. "This is the first step in clinical trials for T cell therapy in the United States," Kwon said. "We will continue to make efforts to allow immunocompromised medicines, starting with the VientiCell application."

The KOSDAQ for clinical funding is also a preliminary one. On December 15, he passed a pre-test of the Korean Stock Exchange and confirmed the planned value of 27.6 billion won to 36.4 billion won. He said: "The purpose of the list is to manage transparency and contribute to the growth of the company," he said. "From 2022 to the beginning of production and technological exports, etc. Growth from 2013," We will achieve our vision. "

[ad_2]

Source link